8-K: BrainStorm Cell Therapeutics Announces Positive Regulatory Progress and Second Quarter 2024 Financial Results

BrainStorm Cell Therapeutics reports alignment with the FDA on key aspects of its Phase 3b trial for NurOwn in ALS, alongside its second quarter 2024 financial results.

Summary

• BrainStorm Cell Therapeutics announced its second quarter 2024 financial results and provided a corporate update.
• The company reached an agreement with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn in ALS.
• A Special Protocol Assessment (SPA) is in place for the Phase 3b NurOwn trial in ALS, validating the clinical trial protocol and statistical analysis.
• The company has enhanced its leadership team with the appointment of Hartoun Hartounian Ph.D. as EVP and Chief Operating Officer, and the promotion of Dr. Bob Dagher to EVP and Chief Medical Officer.
• BrainStorm completed a registered direct offering, raising gross proceeds of $4.0 million.
• Cash, cash equivalents, and restricted cash amounted to approximately $3.65 million as of June 30, 2024.
• Research and development expenses were $0.9 million for the second quarter of 2024, compared to $2.8 million for the same period in 2023.
• The net loss for the second quarter of 2024 was $2.5 million, compared to a net loss of $5.3 million for the second quarter of 2023.
• Net loss per share for the second quarter of 2024 was $0.04, compared to $0.13 for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant regulatory progress and improved financial metrics. However, the low cash balance and ongoing losses temper the overall sentiment.

Positives

• The company has made significant progress in preparing for the Phase 3b trial of NurOwn in ALS.
• The FDA agreement on CMC aspects and the SPA significantly derisk the regulatory pathway for NurOwn.
• The company has secured a leading CRO and is actively working to establish multiple trial sites.
• The company has strengthened its leadership team with key appointments.
• The company successfully raised $4.0 million through a registered direct offering.
• The company has reduced its net loss from $5.3 million to $2.5 million year over year.
• Research and development expenses have decreased from $2.8 million to $0.9 million year over year.

Negatives

• The company's cash position is relatively low at $3.65 million.
• The company continues to operate at a loss, with a net loss of $2.5 million for the quarter.
• The company has a significant accumulated deficit of $220.955 million.

Risks

• The company's ability to raise additional capital is crucial for its continued operations and the execution of the Phase 3b trial.
• The success of the Phase 3b trial is not guaranteed, and there are risks associated with clinical trials.
• Regulatory approvals are not guaranteed, and the FDA may not approve NurOwn.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and achieve positive clinical trial results.
• The company's financial position is weak with a low cash balance and significant accumulated deficit.

Future Outlook

The company is focused on initiating and executing the Phase 3b trial for NurOwn in ALS and believes that the regulatory aspects of the program have been substantially derisked. The company is actively working to establish multiple trial sites and is on track to meet production timelines.

Management Comments

• We continue to make excellent progress in our preparations for the planned Phase 3b trial of NurOwn in ALS, with important recent developments on regulatory and operational fronts, said Chaim Lebovits, President and CEO of BrainStorm.
• We believe that the regulatory aspects of the program have been substantially derisked, having secured agreement with the FDA on a Special Protocol Assessment and also reached alignment on the CMC aspects.
• If successful, this trial has the potential to significantly improve the lives of ALS patients by providing a much-needed therapeutic option.

Industry Context

This announcement is significant for the ALS treatment landscape, as NurOwn represents a novel approach using autologous stem cell therapy. The positive regulatory developments and progress towards a Phase 3b trial are important steps in potentially bringing a new treatment option to patients with this debilitating disease. The company is competing with other companies developing ALS treatments, including gene therapies and small molecule drugs.

Comparison to Industry Standards

• The FDA's SPA agreement for the Phase 3b trial is a positive sign, as it indicates that the trial design and statistical analysis are deemed adequate for a future BLA submission, which is a critical step for regulatory approval.
• The company's progress in securing a leading CRO and engaging with multiple ALS centers of excellence is in line with industry best practices for conducting clinical trials.
• The reduction in R&D expenses and net loss compared to the previous year is a positive trend, but the company's cash position remains a concern compared to other biotech companies in the clinical trial phase.
• Other companies in the ALS space, such as Amylyx Pharmaceuticals (AMX) with Relyvrio, have achieved regulatory approval, setting a benchmark for BrainStorm's future goals. Biogen (BIIB) is also a major player in the neurodegenerative disease space, and their success with other therapies provides a context for BrainStorm's challenges and opportunities.

Management Changes

Stakeholder Impact

• Shareholders may view the regulatory progress and improved financial metrics positively.
• Employees may be encouraged by the company's progress and leadership changes.
• ALS patients and their families may be hopeful about the potential of NurOwn as a treatment option.
• Creditors may be concerned about the company's low cash balance and ongoing losses.

Next Steps

• The company will continue to prepare for the initiation of the Phase 3b trial of NurOwn in ALS.
• The company will work to establish multiple trial sites.
• The company will continue to engage with the FDA and other regulatory bodies.

Key Dates

Keywords

NurOwn, ALS, Phase 3b trial, FDA, Special Protocol Assessment, CMC, Clinical Research Organization, Biomarker, Registered Direct Offering, Neurodegenerative Diseases, Stem Cell Therapy